Viva Biotech Holdings (HKG:1873) shareholder returns have been strong, earning 143% in 1 year

The last three months have been tough on Viva Biotech Holdings (HKG:1873) shareholders, who have seen the share price decline a rather worrying 31%. But that doesn't detract from the splendid returns of the last year. During that period, the share price soared a full 143%. So we think most shareholders won't be too upset about the recent fall. More important, going forward, is how the business itself is going.

On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

During the last year Viva Biotech Holdings grew its earnings per share, moving from a loss to a profit.

When a company has just transitioned to profitability, earnings per share growth is not always the best way to look at the share price action.

Viva Biotech Holdings' revenue actually dropped 7.9% over last year. So the fundamental metrics don't provide an obvious explanation for the share price gain.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

We know that Viva Biotech Holdings has improved its bottom line lately, but what does the future have in store? So it makes a lot of sense to check out what analysts think Viva Biotech Holdings will earn in the future (free profit forecasts).

A Different Perspective

It's nice to see that Viva Biotech Holdings shareholders have received a total shareholder return of 143% over the last year. Notably the five-year annualised TSR loss of 12% per year compares very unfavourably with the recent share price performance. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Viva Biotech Holdings you should know about.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.